Bleeding and venous thromboembolism arising in acutely ill hospitalized medical patients. Findings from the Spanish national discharge database

Eur J Intern Med. 2014 Feb;25(2):137-41. doi: 10.1016/j.ejim.2013.10.004. Epub 2013 Nov 4.

Abstract

Background: There is scarce evidence to identify which acutely ill medical patients might benefit from prophylaxis against venous thromboembolism (VTE).

Methods: The Spanish National Discharge Database was used to identify predictors of bleeding and VTE during hospitalization for an acute medical illness.

Results: Of 1,148,301 patients, 3.10% bled, 1.21% were diagnosed with VTE, and 8.64% died. The case-fatality rate was: 20.8% for bleeding and 19.7% for VTE. Eight clinical variables were independently associated with an increased risk for VTE and bleeding, one with a decreased risk for both events, 4 with an increased risk for VTE and a decreased risk for bleeding, 2 with an increased risk for bleeding but a decreased risk for VTE, and 1 with a decreased risk for bleeding. When all these variables were considered, we composed a risk scoring system, in which we assigned points to each variable according to the ratio between the odds ratio for bleeding and for VTE. Overall, 21% of patients scored less than 0 points and had a bleeding vs. VTE ratio of 1.19; 55% scored 0 to 1.0 points and had a ratio of 2.13; and 24% scored over 1.0 points and had a ratio of 6.10.

Conclusions: A risk score based on variables documented at admission can identify patients with different ratios (near 1.0; about 2.0; and >6.0) between the rate of bleeding and of VTE.

Keywords: Bleeding; Medical patients; Scoring; Venous thromboembolism.

MeSH terms

  • Acute Disease
  • Aged
  • Aged, 80 and over
  • Anticoagulants / therapeutic use
  • Chemoprevention
  • Comorbidity
  • Databases, Factual
  • Female
  • Fondaparinux
  • Heart Failure / epidemiology*
  • Hemorrhage / epidemiology*
  • Heparin / therapeutic use
  • Heparin, Low-Molecular-Weight / therapeutic use
  • Hospitalization / statistics & numerical data*
  • Humans
  • Male
  • Middle Aged
  • Polysaccharides / therapeutic use
  • Pulmonary Embolism / epidemiology*
  • Pulmonary Embolism / prevention & control
  • Respiratory Insufficiency / epidemiology*
  • Risk Assessment
  • Risk Factors
  • Spain / epidemiology
  • Venous Thromboembolism / epidemiology*
  • Venous Thromboembolism / prevention & control
  • Venous Thrombosis / epidemiology*
  • Venous Thrombosis / prevention & control

Substances

  • Anticoagulants
  • Heparin, Low-Molecular-Weight
  • Polysaccharides
  • Heparin
  • Fondaparinux